Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
Iradimed Corporation (IRMD) provides essential medical technologies for MRI environments through its innovative devices. This news hub offers investors and healthcare professionals timely updates on product developments, financial performance, and operational milestones.
Access official press releases and verified news about IRMD's MRI-compatible infusion systems, patient monitoring solutions, and regulatory achievements. Stay informed about quarterly earnings, partnership announcements, and clinical validation studies that demonstrate the company's market leadership.
Key updates include FDA clearances, international expansion efforts, and technological enhancements to the company's non-magnetic device ecosystem. Content is organized chronologically showcase IRMD's progress in improving MRI safety standards while maintaining financial transparency.
Bookmark this page for direct access to primary source materials from Iradimed Corporation. Check regularly for updates on innovations addressing critical needs in diagnostic imaging and patient care during magnetic resonance procedures.
IRADIMED (NASDAQ: IRMD) reported record Q3 2024 revenue of $18.3 million, up 11% year-over-year. The company achieved GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43. Management raised full-year 2024 guidance, expecting revenue between $72.7-73.1 million and GAAP diluted EPS of $1.49-1.52. The company declared a quarterly dividend of $0.15 per share. Domestic sales represented 83% of total revenue, with gross profit margin at 77.4%. The company's MRI-compatible IV infusion pump systems showed strong performance, contributing significantly to the quarter's success.
IRADIMED (NASDAQ: IRMD) has scheduled its 2024 third quarter financial results conference call for October 31st, 2024. The company will release its financial results before market opening, followed by a management-hosted conference call at 11:00 a.m. Eastern Time. Interested participants can register for the call through a provided link, after which they will receive dial-in details and instructions. The call will be available real-time via the internet on the company's website, and a recording will be accessible afterward.
IRADIMED (NASDAQ: IRMD), a leading provider of innovative MRI-compatible medical devices, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place on October 9, 2024, at the Metropolitan Club in New York.
Iradimed's CFO, Jack Glenn, will be hosting one-on-one meetings with investors during the conference. This participation demonstrates Iradimed's commitment to engaging with the investment community and showcasing its innovative products in the healthcare sector.
The conference provides an excellent platform for Iradimed to connect with potential investors and discuss its advancements in MRI-compatible medical devices. It also offers an opportunity for the company to highlight its market position and growth strategies in the healthcare technology industry.
Iradimed (NASDAQ: IRMD), a leader in MRI-compatible medical devices, announced its participation in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference. The event will be held at the Yale Club in New York on September 12, 2024. Iradimed's management team will conduct one-on-one meetings with investors during the conference.
IRADIMED (NASDAQ: IRMD) reported record Q2 2024 financial results, with revenue of $17.9 million, up 11.2% year-over-year. The company achieved GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42. Operating income increased by 13.4% to $5.6 million. IRADIMED declared a quarterly cash dividend of $0.15 per share.
For Q3 2024, the company expects revenue between $18.0-$18.2 million and GAAP diluted EPS of $0.34-$0.37. The full-year 2024 guidance remains unchanged, with expected revenue of $72.0-$74.0 million and GAAP diluted EPS of $1.37-$1.47. The strong performance was driven by growth in the IV infusion pump product line and continued strength in gross margins.
IRADIMED (NASDAQ: IRMD) has announced its upcoming 2024 second quarter financial results conference call, scheduled for August 1, 2024. The company will release its financial results before the market opens on that day. The conference call, hosted by Iradimed management, will begin at 12:00 p.m. Eastern Time.
Interested individuals can participate by registering through the provided link. Upon registration, participants will receive a dial-in number, unique pin, and instructions. The call will also be available in real-time via the internet on Iradimed's investor relations website. A recording of the call will be made available on the company's website following its completion.
Iradimed (NASDAQ: IRMD), a leading provider of MRI-compatible medical devices, announced that its common stock will uplist to the Nasdaq Global Market starting June 14, 2024. This move reflects the company's growth and commitment to delivering value to shareholders. Roger Susi, CEO, emphasized that the uplisting enhances Iradimed's market visibility and aligns it with companies of high distinction. Iradimed was previously listed on the Nasdaq Capital Market since its IPO in 2014. The Nasdaq Global Market is known for its rigorous financial and corporate governance standards, including stocks of about 1,450 companies.
IRADIMED reported record revenue of $17.6 million, GAAP diluted EPS of $0.32, and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. The company also declared a regular quarterly cash dividend of $0.15 per share for the second quarter of 2024. The financial results showed an increase in operating income by 18.5% compared to the same period in 2023. The company anticipates strong financial performance for the second quarter and full year of 2024.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
